Welcome to the e-CCO Library!

OP008: An innovative treatment for refractory perianal fistulas in Crohn's disease: local micro reinjection of autologous fat and adipose derived stromal vascular fraction
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Serrero M.*1, Philandrianos C.2, Visee C.3, Veran J.2, Orsoni P.3, Sabatier F.2, Grimaud J.-C.1

Created: Wednesday, 20 February 2019, 10:36 AM
OP008: Detection of mucosal healing with a serum marker panel in adalimumab-treated patients with ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. de Bruyn1,2*, R. Ringold3, E. Martens2, M. Ferrante1,4, G. Van Assche1,4, G. Opdenakker2, A. Dukler3, S. Vermeire1,4

Created: Thursday, 21 February 2019, 9:14 AM
OP008: Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

R. Alberts*1, E. M. de Vries2, G. Alexander3, D. Alvaro4, A. Bergquist5, U. Beuers2, E. Björnsson6, K. M. Boberg7, C. L. Bowlus8, R. W. Chapman9, O. Chazouillères10, A. Cheung11, G. Dalekos12, B. Eksteen13, D. Ellinghaus14, M. Färkkilä15, E. A. Festen1, A. Floreani16, T. Folseraas7, E. Goode17, D. N. Gotthardt18, G. M. Hirschfield19, B. van Hoek20, K. Holm7, S. Hohenester21, J. R. Hov7, F. Imhann1, P. Invernizzi22, X. Jiang7, J. Eaton23, B. D. Juran24, K. N. Lazaridis24, V. Leppa25, J. Z. Liu26, J. Löfberg27, M. P. Manns28, H.-U. Marschall29, M. Marzioni30, A. L. Mason31, E. Melum7, P. Milkiewicz32, T. Müller33, A. Pares34, C. Rupp35, S. M. Rushbrook36, C. Rust37, F. Sampaziotis38, R. N. Sandford39, C. Schramm40, S. Schreiber14, E. Schrumpf7, M. Silverberg41, B. Srivastava39, M. Sterneck42, A. Teufel43, L. Tittmann44, L. Vallier38, A. V. Vila1, B. de Vries1, T. J. Weismüller28, C. Wijmenga45, K. Zachou46, A. Franke14, C. A. Anderson47, T. H. Karlsen7, C. Y. Ponsioen2, R. K. Weersma1

Created: Friday, 22 February 2019, 9:49 AM
OP009: A combination of clinical, serological, and genetic factors predicts complicated disease course in paediatric-onset Crohn’s disease: results from a population-based study
Year: 2018
Source: ECCO '18 Vienna
Authors:

H. Sarter1,2*, G. Savoye3, D. Turck2,4, F. Vasseur5, G. Marot6,7, B. Pariente2,8, S. Singh9, J.F. Colombel10, C. Gower-Rousseau1,2, M. Fumery11

Created: Thursday, 21 February 2019, 9:14 AM
OP009: Gene-microbiome interactions underlying the onset and the clinical phenotypes of inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

F. Imhann*1, A. Vich Vila1, M. J. Bonder2, D. Gevers3, J. Fu2, M. C. Visschedijk1, L.M. Spekhorst1, L. Franke2, H. van Dullemen1, R. W. F. Ter Steege1, C. Huttenhower4, G. Dijkstra1, R. J. Xavier3, C. Wijmenga2, E. A. M. Festen1, A. Zhernakova2, R. K. Weersma1

Created: Friday, 22 February 2019, 9:49 AM
OP009: Long-term efficacy and safety of Cx601, allogeneic expanded adipose-derived mesenchymal stem cells, for complex perianal fistulas in Crohn's disease: 52-week results of a phase III randomised controlled trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Panes J.*1, García-Olmo D.2, Van Assche G.3, Colombel J.-F.4, Reinisch W.5, Baumgart D.C.6, Nachury M.7, Ferrante M.3, Kazemi-Shirazi L.5, Grimaud J.C.8, de la Portilla F.9, Goldin E.10, Richard M.P.11, Diez M.C.11, Danese S.12

Created: Wednesday, 20 February 2019, 10:36 AM
OP01 Higher vs. standard adalimumab maintenance regimens in patients with moderately to severely active ulcerative colitis: Results from the SERENE-UC maintenance study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J.F. Colombel1, J. Panés2, G. D’Haens3, S. Schreiber4, R. Panaccione5, L. Peyrin-Biroulet6, E.V. Loftus Jr7, S. Danese8, E. Louis9, A. Armuzzi10, M. Ferrante11, H. Vogelsang12, J. Lefebvre13, T. Doan14, W. Xie15, B. Huang15, J. Petersson16, J. Kalabic17, A. Robinson18, W.J. Sandborn19

Created: Thursday, 30 January 2020, 10:12 AM
OP010: Azathioprine dose reduction in patients with inflammatory bowel disease on combination therapy: a prospective study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

E. Del Tedesco1, S. Paul2, H. Marotte3, C. Jarlot1, N. Williet4, J. M. Phelip4, L. Peyrin Biroulet5, J. F. Colombel6, X. Roblin*4

Created: Friday, 22 February 2019, 9:49 AM
OP010: Long term efficacy and safety of Ustekinumab for Crohn's disease: results from IM-UNITI long-term extension through 2 years
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sandborn W.1, Rutgeerts P.2, Gasink C.3, Jacobstein D.3, Gao L.-L.3, Johanns J.3, Sands B.4, Hanauer S.B.5, Targan S.6, Ghosh S.7, de Villiers W.J.S8, Colombel J.-F.4, Feagan B.G.*9

Created: Wednesday, 20 February 2019, 10:36 AM
OP010: Shallow whole-genome sequencing predicts the future cancer risk of low-grade dysplastic lesions arising in ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

I. Al Bakir1,2*, K. Curtius1, A.-M. Baker1, T.S.O. Clarke1, M. Moorghen3, M. Jansen4, M. Rodriguez-Justo4, S. Leedham5, T. Graham1*, A. Hart2*

Created: Thursday, 21 February 2019, 9:14 AM
OP011: Comparison of adalimumab monotherapy and a combination with azathioprine for patients with Crohns disease: a prospective, multicentre, open-labelled clinical trial (DIAMOND study)
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

T. Matsumoto*1, S. Motoya2, K. Watanabe3, T. Hisamatsu4, H. Nakase5, N. Yoshimura6, T. Ishida7, S. Kato8, T. Nakagawa9, M. Esaki10, M. Nagahori11, T. Matsui12, Y. Naito13, T. Kanai14, Y. Suzuki15, M. Nojima16, M. Watanabe11, T. Hibi17

Created: Friday, 22 February 2019, 9:49 AM
OP011: Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Peyrin-Biroulet L.*1, Feagan B.G.2, Mansfield J.3, Rubin D.T.4, Arulmani U.5, Maciuca R.5, Tyrrell H.6, Thommes J.5, Tole S.6

Created: Wednesday, 20 February 2019, 10:36 AM
OP011: Integration of whole-exome sequencing and RNA sequencing of intestinal biopsies in inflammatory bowel disease identifies inflammation-dependent effects
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Barbieri1*, W. Uniken Venema1, A. Vich Vila1, Y. Li1, L. Franke1, F. van Dijk1, N. De Klein1, M. Swertz1, S. Sanna1, M.D. Voskuil1, M. Rivas2, R. Xavier2, M. Daly2, G. Dijkstra1, E.A. Festen1, R.K. Weersma1

Created: Thursday, 21 February 2019, 9:14 AM
OP012: IL-23 is centrally involved in mediating molecular resistance to anti-TNF therapy in Crohn’s disease patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

H. Schmitt1*, U. Billmeier1, W. Dieterich1, T. Rath1, S. Sonnewald2, S. Reid2, S. Hirschmann1, K. Hildner1, M.J. Waldner1, J. Mudter3, A. Hartmann4, R. Grützmann5, C. Neufert1, T. Münster6, M.F. Neurath1, R. Atreya1

Created: Thursday, 21 February 2019, 9:14 AM
OP012: Perioperative use of vedolizumab is not associated with short-term postoperative infectious complications in patients with ulcerative colitis undergoing (procto)colectomy with ileal pouch-anal anastomosis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ferrante M.*1, Schils N.1, De Buck van Overstraeten A.2, Vermeire S.1, Van Assche G.1, Wolthuis A.2, D'Hoore A.2

Created: Wednesday, 20 February 2019, 10:36 AM
OP012: Risk factors for colorectal neoplasia in ulcerative colitis: results from the largest and longest-running colonoscopic surveillance programme
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. H. R. Choi*1, 2, I. Al Bakir1, 2, N. S. J. Ding1, M. Moorghen1, S. Thomas-Gibson1, J. Warusavitarne1, B. Saunders1, M. Rutter3, T. Graham2, A. Hart1

Created: Friday, 22 February 2019, 9:49 AM
OP013: Disease management and outcomes of patients with Crohn's disease at high risk of recurrence. Results from PRACTICROHN study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Iborra M.*1, Martín Arranz M.D.2, Domènech E.3, García V.4, Gutiérrez A.5, Barreiro-de Acosta M.6, Cea-Calvo L.7, Romero C.7, Juliá B.7

Created: Wednesday, 20 February 2019, 10:36 AM
OP013: Evolution of corticosteroid use in Crohns disease patients between 1991 and 2014: results from the Dutch population-based Inflammatory Bowel Disease South Limburg cohort
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Jeuring*1, 2, V. Biemans1, L. Liu1, T. Van den Heuvel1, 2, M. Zeegers3, 4, 
W. Hameeteman1, M. Romberg-Camps5, L. Oostenbrug6, A. Masclee1, 2, D. Jonkers1, 2, M. Pierik1, 2

Created: Friday, 22 February 2019, 9:49 AM
OP013: HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Sazonovs1*, N.A. Kennedy2, C. Bewshea2, L. Moutsianas1, G.J. Walker2, K. De Lange1, J. Goodhand2, C. Anderson1, J. Barrett1, PANTS Investigator Consortium, T. Ahmad2

Created: Thursday, 21 February 2019, 9:14 AM
OP014: A multicentre, double-blind, placebo-controlled phase 3 study of ustekinumab, a human interleukins-12/23p40 mab, in moderate-severe Crohns disease refractory to anti-tumour necrosis factor α: UNITI-1
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Rutgeerts*1, C. Gasink2, M. Blank3, Y. Lang2, J. Johanns2, L.-L. Gao2, B. Sands4, S. Hanauer5, B. Feagan6, S. Targan7, S. Ghosh8, W. de Villiers9, J.-F. Colombel10, S. Lee11, P. Desreumaux12, E. V. Loftus, Jr13, S. Vermeire14, W. J. Sandborn15

Created: Friday, 22 February 2019, 9:49 AM